Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

Authors: Luca Ceriani, Lisa Milan, Maurizio Martelli, Andrés J.M. Ferreri, Luciano Cascione, Pier Luigi Zinzani, Alice Di Rocco, Annarita Conconi, Anastasios Stathis, Franco Cavalli, Monica Bellei, Kelly Cozens, Elena Porro, Luca Giovanella, Peter Johnson, Emanuele Zucca - Blood 2018 cited by 111

< .001) retained statistical significance. Using these 2 features to construct a simple prognostic model resulted in early and accurate (positive predictive value, 89%; negative predictive value, ≥90%) identification of patients at high risk for progression at a point that would allow the use of risk-adapted treatments. This may provide an important opportunity for the design of future trials aimed at helping the minority of patients who harbor chemorefractory PMBCL. The study is registered at ClinicalTrials.gov as NCT00944567.